MinorAntifungals, triazole derivatives×Gabapentinoids (antiepileptics)
Updated · Methodology
Mechanism
Pregabalin undergoes negligible metabolism: less than 2% of a dose appears in the urine as metabolites and the rest is excreted unchanged by the kidneys. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro. According to its SmPC, it is unlikely to cause or be subject to pharmacokinetic interactions (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). Fluconazole is a moderate inhibitor of CYP2C9 and CYP3A4 and a potent inhibitor of CYP2C19. It is itself hardly metabolised: about 80% of a dose appears unchanged in the urine (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). Pregabalin does not depend on these enzymes, so their inhibition by fluconazole does not affect it.
Symptoms
The documents describe no symptoms caused by this combination. Pregabalin causes dizziness and somnolence, which can increase the risk of falls in older people. Loss of consciousness and confusion have been reported after marketing (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). Fluconazole has rarely caused serious liver toxicity, mainly in people with serious underlying illness, and it has usually been reversible once fluconazole was stopped (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of fluconazole or pregabalin is needed. Neither document names the pair, and the two drugs share no metabolic pathway (pregabalin SmPC, European Medicines Agency, EMA; fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). People taking pregabalin are advised to be careful until they know how it affects them. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, sections 4.2, 4.4 and 5.2). If liver function tests become abnormal during fluconazole treatment, the person is monitored for signs of more serious liver injury (fluconazole SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fluconazol (nº registro 67929), sección 4.5 (2026)– AEMPS, CIMA, nº registro 67929, revisión 10/2026, sección 4.5
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5